%0 Journal Article
%B ERJ Open Res
%D 2022
%G eng
%M 35141324
%R 10.1183/23120541.00606-2021
%T Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population
%V 8
%2 PMC8819252 National Institute for Health Research; and consulting fees and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events received from Boehringer Ingelheim, outside the submitted work. M. Bafadhel reports grants or contracts from AZ; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from AZ, GSK, Chiesi, Cipla and Roche; participation on a Data Safety Monitoring Board or Advisory Board for AZ and GSK; and stock or stock options held for Albus Health; all outside the submitted work. I.D. Pavord reports support from Sanofi and Regeneron Pharmaceuticals, Inc., and nonfinancial support from Excerpta Medica, during the conduct of the study; and other support from Aerocrine AB, Almirall, AstraZeneca and Boehringer Ingelheim, grants and other support from Chiesi, other support from GSK, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi, Teva, Circassia, Dey Pharma, Genentech, Knopp Biosciences, Merck, MSD, Napp Pharmaceuticals, RespiVert and Schering-Plough, outside the submitted work. The remaining authors have nothing to disclose.
%7 2022/02/11
%@ 2312-0541 (Print)
2312-0541